Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Betta Pharmaceuticals Co. Ltd.

en.bettapharma.com

Latest From Betta Pharmaceuticals Co. Ltd.

Bookmark
  • Interviews

Breaking Away From Betta, Jacobio Raises China Oncology Development Bar

By Brian Yang

Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.

StartUps and SMEs Cancer
Bookmark
  • Interviews

Hepalink-Backed HighTide Bets On NASH For Global Markets

By Brian Yang

Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.

China Liver & Hepatic
Bookmark
  • News

Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m

By Deanna Kamienski, Beth Allan and Maureen Riordan

Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals... 

Deals Financing
Bookmark
  • Analysis

Choose Carefully For China Drug Development Success: White Paper

By Brian Yang

By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes a recent white paper from investment bank China E-Capital.

China Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Zhejiang Beta Pharma Co. Ltd.
  • Beta Pharmaceutical Inc.
  • Zhejiang Beta Pharma Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Betta Pharmaceuticals Co. Ltd.
  • Senior Management
  • Lieming Ding, MD, CEO
  • Contact Info
  • Betta Pharmaceuticals Co. Ltd.
    Phone: 571 8613 0357
    355 Xingzhong Rd., Yuhang Economic Zone
    Hangzhou,
    China
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By